US House ban on pay-for-delay settlements upsets pharma
This article was originally published in Scrip
The US House of Representatives has cleared a controversial measure that, if signed into law, would ban "pay for delay" settlements between brand-name pharmaceutical companies and their generic competitors aimed at delaying the entry of generic medicines onto the market.
You may also be interested in...
A new EU pilot will help drug regulators and policymakers understand the factors influencing the uneven availability of centrally authorized medicines in the member states.
A damning UK report makes uncomfortable reading about how thousands of women suffered avoidable harm from the anti-epileptic drug sodium valproate and two other medical interventions and how safety concerns raised were dismissed, overlooked and ignored.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.